05.01.05
Nutrition 21, Purchase, NY, and XLHealth Corporation, Baltimore, MD, have made an agreement in principle for a program that will make Diachrome available to physicians for people with diabetes participating in the Center for Medicare and Medicaid (CMS) sponsored Chronic Care Improvement Program (CCIP) in Tennessee. The state ranks 2nd in the nation with persons diagnosed with diabetes, and spends approximately $3.6 billion on direct and indirectly associated healthcare costs. The CCIP is the first large-scale chronic care improvement initiative under the Medicare fee-for-service (FFS program).
In other news, Nutrition 21 has been granted “derogation” (approval for continued sale) for Chromax chromium picolinate in England, Scotland, Wales and Northern Ireland by the U.K.’s Food Standards Agency (FSA). The FSA approval provides a four-year window in which the company can continue to sell Chromax, while the European Food Safety Authority (EFSA) reviews the dossier. If approved by the EFSA, it will result in the formal adoption of Chromax as an approved source of trivalent chromium into EU legislation. Nutrition 21 will also request approval in other countries, including Austria, Germany and Ireland during the EFSA review process.
In other news, Nutrition 21 has been granted “derogation” (approval for continued sale) for Chromax chromium picolinate in England, Scotland, Wales and Northern Ireland by the U.K.’s Food Standards Agency (FSA). The FSA approval provides a four-year window in which the company can continue to sell Chromax, while the European Food Safety Authority (EFSA) reviews the dossier. If approved by the EFSA, it will result in the formal adoption of Chromax as an approved source of trivalent chromium into EU legislation. Nutrition 21 will also request approval in other countries, including Austria, Germany and Ireland during the EFSA review process.